Moreover, it has been demonstrated that TKIs, such as Gefitinib (GEF) and Erlotinib (ERL), have a notable benefit as a treatment for EGFR mutation-positive tumors compared to the traditional combined platinum-based chemotherapy, making the TKIs a first-line treatment in EGFR-mutated NSCLC [4,5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.